Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: Clin Cancer Res. 2010 Mar 23;16(7):2122–2130. doi: 10.1158/1078-0432.CCR-09-2765

Fig. 2.

Fig. 2

Gal-1 is detected by intracellular flow cytometry in MLL-rearranged B-ALL cell lines and primary tumors. Intracellular flow cytometry was performed on B-ALL cell lines (A) and viable primary tumor specimens from four B-ALL patients with known MLL translocation status (B). B, mean fluorescence intensity for control and anti–Gal-1 immunostaining was as follows: P1, 21.5 versus 108; P2, 24.2 versus 117; P3, 20.3 versus 35.5; and P4, 26.6 versus 63.3.